Market Cap
$300.2M
ABEO
ABEONA THERAPEUTICS INC.
$5.01 ▲ +0.00%
Prev close $5.01Market cap$300.2M
ConsensusStrong Buy
12-mo target$18.88 (+276.7%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (4 insiders)13 New Institutional Positions9 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ABEO right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
50 funds
Inst. Value
$118.2M
Inst. Activity
13 buys / 9 sells
Insider Activity
$0.00 buy / $2.7M sell
Insider Net $
-$2.7M
Social Sentiment
63° Warm
SEC Reports
16
Press Releases
3
Price chart 30d -15.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today ann
Sep 29, 2026 Insider
Vasanthavada Madhav sold 4,902 shares
Chief Commercial Officer @ $5.16 ($25.3K)
Sep 29, 2026 Insider
O'Malley Brendan M. sold 6,727 shares
SVP, Chief Legal Officer @ $5.16 ($34.7K)
Sep 29, 2026 Insider
Sep 15, 2026 SEC Vazzano Joseph Walter sold 9,191 shares
Chief Financial Officer @ $5.16 ($47.4K)
Abeona Therapeutics filed an 8-K furnishing an updated investor presentation for the H.C. Wainwright 28th Annual Global
8-K — Impact 2/10
Abeona Therapeutics saw a strong institutional accumulation cluster in Q2 2026, with 6 buyers adding $12.5M in net new p
INST-CLUSTER — Impact 5/10
Abeona reported Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ, with five patients treated. However, EPS of -$0.35 m
PRESS-RELEASE — Impact 6/10
Jun 30, 2026 Inst.
OneDigital Investment Advisors LLC — NEW
1,653,024 shares ($10.2M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 12 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 18, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| Sep 17, 2026 | Roth Capital | INITIATE | Buy | 56% |
| Aug 14, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% |
Price targets
Where 8 covering analysts think ABEO trades over the next 12 months.
$18.88 +276.7% upside Strong Buy
Current$5.01 Low$14.00 Median$17.00 High$30.00 8 analysts
$14.00$30.00
Analyst rating Strong Buy· 1.0/5 as of Oct 2, 2026
Social media sentiment mood -6.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
63°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 1 bullish, 2 bearish, 1 mixed, 12 neutral · avg impact 3.7/10.Plus 3 press releases.
NEUTRAL8-K2/10
Abeona Therapeutics filed an 8-K furnishing an updated investor presentation for the H.C. Wainwright
Sep 15, 2026
BULLISHINST-CLUSTER5/10
Abeona Therapeutics saw a strong institutional accumulation cluster in Q2 2026, with 6 buyers adding
Aug 14, 2026
MIXEDPRESS-RELEASE6/10
Abeona reported Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ, with five patients treated. Howe
Aug 13, 2026
NEUTRAL8-K5/10
Abeona reported Q2 2026 net product revenue of $11.4M, up 31% QoQ from $8.7M in Q1 2026, driven by f
Aug 13, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-exe
Oct 1, 2026
short_volume
Short Volume: ABEO — 66.1% short (0.5M / 0.7M)
Short: 475,339 | Exempt: 0 | TRF Vol: 719,558 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: ABEO — 55.2% short (0.3M / 0.6M)
Short: 331,761 | Exempt: 2,313 | TRF Vol: 601,124 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Co
Sep 23, 2026
short_volume
Short Volume: ABEO — 70.5% short (0.4M / 0.5M)
Short: 369,908 | Exempt: 0 | TRF Vol: 525,002 | Short Ratio: 70.5% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.17 | $-0.25–$-0.05 | -57.4% | -27.5% | 2↑ 0↓ | $0.0B | 4 |
| Next Q | $-0.13 | $-0.24–$-0.02 | 65.8% | -33.9% | 2↑ 0↓ | $0.0B | 4 |
| Current FY | $-0.95 | $-1.15–$-0.72 | 23.1% | -8.8% | 0↑ 2↓ | $0.1B | 4 |
| Next FY | $-0.21 | $-0.83–$0.42 | 78.2% | -11.2% | 0↑ 2↓ | $0.1B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.170 | — |
| 7d ago | $-0.113 | -0.058 |
| 30d ago | $-0.133 | -0.037 |
| 60d ago | $-0.110 | -0.060 |
| 90d ago | $-0.110 | -0.060 |
Institutional ownership
Which big funds own ABEO (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $118.2M total value (19,142,170 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, OneDigital. Net buying activity: 13 institutions added/increased vs 9 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 3,352,474 | $20.7M | 17.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,211,433 | $13.7M | 11.6% | — |
| OneDigital Investment Advisors LLC | 1,653,024 | $10.2M | 8.6% | NEW |
| GEODE CAPITAL MANAGEMENT, LLC | 1,261,090 | $7.8M | 6.6% | — |
| GOLDMAN SACHS GROUP INC | 1,224,806 | $7.6M | 6.4% | ADD +55.7% |
| STATE STREET CORP | 1,040,228 | $6.4M | 5.4% | ADD +25.5% |
| Rubric Capital Management LP | 608,771 | $3.8M | 3.2% | — |
| NORTHERN TRUST CORP | 552,630 | $3.4M | 2.9% | ADD +26.8% |
| CITIGROUP INC | 548,300 | $3.4M | 2.9% | — |
| NATIONAL BANK OF CANADA /FI/ | 500,000 | $3.1M | 2.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| OneDigital Investment Advisors LLC | NEW | — | 1,653,024 | — | $10.2M |
| NORTHERN TRUST CORP | ADD | 435,973 | 552,630 | +26.8% | $3.4M |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | 199,145 | 409,075 | +105.4% | $2.5M |
| BARCLAYS PLC | DOUBLED | 27,248 | 356,427 | +1208.1% | $2.2M |
| CITADEL ADVISORS LLC | DOUBLED | 55,837 | 259,401 | +364.6% | $1.6M |
| ExodusPoint Capital Management, LP | ADD | 122,944 | 212,325 | +72.7% | $1.3M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 425,426 | 211,335 | -50.3% | $1.3M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | TRIM | 432,370 | 194,377 | -55.0% | $1.2M |
| FMR LLC | TRIM | 194,813 | 138,497 | -28.9% | $855.9K |
| SEI INVESTMENTS CO | TRIM | 172,460 | 105,560 | -38.8% | $652.4K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 34 transactions. Net -$2.7M — $0.00 bought, $2.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Vasanthavada Madhav | Chief Commercial Officer | SELL | 4,902 | $5.16 | $25.3K |
| Sep 29, 2026 | O'Malley Brendan M. | SVP, Chief Legal Officer | SELL | 6,727 | $5.16 | $34.7K |
| Sep 29, 2026 | Vazzano Joseph Walter | Chief Financial Officer | SELL | 9,191 | $5.16 | $47.4K |
| Sep 29, 2026 | Seshadri Vishwas | Chief Executive Officer | SELL | 19,608 | $5.16 | $101.1K |
| Sep 1, 2026 | Alvino Mark | Director | SELL | 15,000 | $5.86 | $88.0K |
| Jul 21, 2026 | Vazzano Joseph Walter | Chief Financial Officer | SELL | 1,478 | $6.53 | $9.7K |
| Jul 9, 2026 | O'Malley Brendan M. | SVP, Chief Legal Officer | SELL | 12,050 | $6.96 | $83.9K |
| Jul 9, 2026 | Seshadri Vishwas | Chief Executive Officer | SELL | 67,971 | $6.96 | $473.3K |
| Jul 9, 2026 | Vazzano Joseph Walter | Chief Financial Officer | SELL | 24,880 | $6.96 | $173.3K |
| Jul 9, 2026 | Vasanthavada Madhav | Chief Commercial Officer | SELL | 12,606 | $6.96 | $87.8K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ABEO.
Shares short
15,745,098
Settlement Sep 15, 2026
Change vs prior
+3.9%
Semi-monthly cycle
Days to cover
12.0
At avg daily volume
Of shares outstanding
≈27.5%
Estimate — not % of float
All ABEO filing & press-release reports (19)
- 8-K reportSep 15, 2026
- INST-CLUSTER reportAug 14, 2026
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 13, 2026
- CLUSTER reportJul 9, 2026
- CLUSTER reportJun 17, 2026
- CLUSTER reportJun 15, 2026
- 8-K reportJun 12, 2026
- 8-K reportJun 10, 2026
- CLUSTER reportJun 10, 2026
- 8-K reportJun 4, 2026
- CLUSTER reportMay 22, 2026
- PRESS-RELEASE reportMay 13, 2026
- 8-K reportMay 13, 2026
- DEFA14A reportMay 4, 2026
- 8-K reportApr 7, 2026
- PRESS-RELEASE reportApr 2, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 3, 2026